{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:17:35Z","timestamp":1788023855020,"version":"build-2784847793"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10787-025-01675-4","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T11:03:03Z","timestamp":1741172583000},"page":"1617-1672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-9778","authenticated-orcid":false,"given":"Alireza","family":"Jafarzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6545-3460","authenticated-orcid":false,"given":"Elham","family":"Behrangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8250-9385","authenticated-orcid":false,"given":"Mina","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Falakeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine Khalilnejad","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-4429","authenticated-orcid":false,"given":"Azadeh","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"1675_CR76","doi-asserted-by":"crossref","unstructured":"Almutairi N (2019) Atopic dermatitis and related disorders: special types of presentation. Harper's textbook of pediatric dermatology, vol 20. pp 228\u201344","DOI":"10.1002\/9781119142812.ch17"},{"issue":"3","key":"1675_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000503062","volume":"236","author":"N AlMutairi","year":"2020","unstructured":"AlMutairi N, Nour T (2020) Tofacitinib in pediatric psoriasis: an open-label trial to study its safety and efficacy in children. Dermatology 236(3):191\u2013198. https:\/\/doi.org\/10.1159\/000503062","journal-title":"Dermatology"},{"issue":"10","key":"1675_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.80666","volume":"11","author":"AS Bazargan","year":"2023","unstructured":"Bazargan AS, Jafarzadeh A, Nobari NN (2023) Successful treatment of resistant plantar ulcerative lichen planus with tofacitinib: a case report and comprehensive review of the literature. Clin Case Rep 11(10):e8066. https:\/\/doi.org\/10.1002\/ccr3.80666","journal-title":"Clin Case Rep"},{"key":"1675_CR74","doi-asserted-by":"crossref","unstructured":"Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, Gherardi G, Xiao J, Dingman R, Xu C, Avetisova E (2024) Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol 160(8):805\u2013812","DOI":"10.1001\/jamadermatol.2024.1536"},{"issue":"1","key":"1675_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2024.08.005","volume":"155","author":"LA Beck","year":"2025","unstructured":"Beck LA, Muraro A, Boguniewicz M, Chen Z, Zahn J, Rodr\u00edguez Marco A (2025) Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 155(1):135\u2013143. https:\/\/doi.org\/10.1016\/j.jaci.2024.08.005","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1675_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13718","volume":"30","author":"E Behrangi","year":"2024","unstructured":"Behrangi E, Moodi F, Jafarzadeh A, Goodarzi A (2024) Paradoxical and bimodal immune-mediated dermatological side effects of TNF-\u03b1 inhibitors: a comprehensive review. Skin Res Technol 30(5):e13718. https:\/\/doi.org\/10.1111\/srt.13718","journal-title":"Skin Res Technol"},{"issue":"3","key":"1675_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","volume":"23","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J et al (2022) Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol 23(3):365\u2013383. https:\/\/doi.org\/10.1007\/s40257-022-00683-2","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1675_CR6","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/jdv.17002","volume":"35","author":"C Bodemer","year":"2021","unstructured":"Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E et al (2021) Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol 35(4):938\u2013947. https:\/\/doi.org\/10.1111\/jdv.17002","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1675_CR7","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/art.41004","volume":"71","author":"PA Brogan","year":"2019","unstructured":"Brogan PA, Hofer M, Kuemmerle-Deschner JB, Kone-Paut I, Roesler J, Kallinich T et al (2019) Rapid and sustained long-term efficacy and safety of canakinumab in patients with cryopyrin-associated periodic syndrome ages five years and younger. Arthritis Rheumatol 71(11):1955\u20131963. https:\/\/doi.org\/10.1002\/art.41004","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1675_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/art.41901","volume":"74","author":"P Brogan","year":"2022","unstructured":"Brogan P, Yeung RSM, Cleary G, Rangaraj S, Kasapcopur O, Hersh AO et al (2022) phase IIa global study evaluating rituximab for the treatment of pediatric patients with granulomatosis with polyangiitis or microscopic polyangiitis. Arthritis Rheumatol 74(1):124\u2013133. https:\/\/doi.org\/10.1002\/art.41901","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1675_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13063-017-1809-7","volume":"18","author":"S Chan","year":"2017","unstructured":"Chan S, Cornelius V, Chen T, Radulovic S, Wan M, Jahan R et al (2017) Atopic dermatitis anti-IgE paediatric trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial. Trials 18(1):136. https:\/\/doi.org\/10.1186\/s13063-017-1809-7","journal-title":"Trials"},{"issue":"1","key":"1675_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","volume":"174","author":"S Chan","year":"2020","unstructured":"Chan S, Cornelius V, Cro S, Harper JI, Lack G (2020) Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA Pediatr 174(1):29\u201337. https:\/\/doi.org\/10.1001\/jamapediatrics.2019.4476","journal-title":"JAMA Pediatr"},{"issue":"1","key":"1675_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/bjd.18476","volume":"182","author":"MJ Cork","year":"2020","unstructured":"Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD et al (2020) Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol 182(1):85\u201396. https:\/\/doi.org\/10.1111\/bjd.18476","journal-title":"Br J Dermatol"},{"issue":"5","key":"1675_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/bjd.19460","volume":"184","author":"MJ Cork","year":"2021","unstructured":"Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Sun X, Chen Z et al (2021) Dupilumab provides favourable long-term safety and efficacy in children aged >\/= 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol 184(5):857\u2013870. https:\/\/doi.org\/10.1111\/bjd.19460","journal-title":"Br J Dermatol"},{"issue":"3","key":"1675_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/jdv.17792","volume":"36","author":"MJ Cork","year":"2022","unstructured":"Cork MJ, McMichael A, Teng J, Valdez H, Rojo R, Chan G et al (2022) Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. J Eur Acad Dermatol Venereol 36(3):422\u2013433. https:\/\/doi.org\/10.1111\/jdv.17792","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1675_CR14","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1007\/s13555-023-01016-9","volume":"13","author":"MJ Cork","year":"2023","unstructured":"Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Chen Z, Thomas RB et al (2023) Dupilumab safety and efficacy in a phase iii open-label extension trial in children 6\u201311 years of age with severe atopic dermatitis. Dermatol Ther (Heidelb) 13(11):2697\u20132719. https:\/\/doi.org\/10.1007\/s13555-023-01016-9","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1675_CR15","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1111\/jdv.18410","volume":"36","author":"M De Graaf","year":"2022","unstructured":"De Graaf M, Janmohamed SR, Schuttelaar MLA et al (2022) Systemic treatment of children and adolescents with atopic dermatitis aged \u22652 years: a Delphi consensus project mapping expert opinion in Northern Europe. J Eur Acad Dermatol Venereol 36(11):2153\u20132165. https:\/\/doi.org\/10.1111\/jdv.18410","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1675_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11882-022-01047-w","volume":"22","author":"J Dodson","year":"2022","unstructured":"Dodson J, Lio PA (2022) Biologics and small molecule inhibitors: an update in therapies for allergic and immunologic skin diseases. Curr Allergy Asthma Rep 22(12):183\u2013193. https:\/\/doi.org\/10.1007\/s11882-022-01047-w","journal-title":"Curr Allergy Asthma Rep"},{"issue":"4","key":"1675_CR17","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.alit.2024.04.006","volume":"73","author":"M Ebisawa","year":"2024","unstructured":"Ebisawa M, Kataoka Y, Tanaka A, Nagao M, Laws E, Mortensen E et al (2024) Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled phase 3 study. Allergol Int 73(4):532\u2013542. https:\/\/doi.org\/10.1016\/j.alit.2024.04.006","journal-title":"Allergol Int"},{"issue":"10","key":"1675_CR18","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R et al (2021) Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol 157(10):1165\u20131173. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2830","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1675_CR19","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.jaad.2023.11.068","volume":"90","author":"L Fiorillo","year":"2024","unstructured":"Fiorillo L, Becker E, de Lucas R, Belloni-Fortina A, Armesto S, Elewski B et al (2024) Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial. J Am Acad Dermatol 90(6):1232\u20131239. https:\/\/doi.org\/10.1016\/j.jaad.2023.11.068","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1675_CR20","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","volume":"34","author":"HM Hoffman","year":"2012","unstructured":"Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y et al (2012) Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 34(10):2091\u20132103. https:\/\/doi.org\/10.1016\/j.clinthera.2012.09.009","journal-title":"Clin Ther"},{"issue":"6","key":"1675_CR21","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/pde.15378","volume":"40","author":"M Hordinsky","year":"2023","unstructured":"Hordinsky M, Hebert AA, Gooderham M, Kwon O, Murashkin N, Fang H et al (2023) Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol 40(6):1003\u20131009. https:\/\/doi.org\/10.1111\/pde.15378","journal-title":"Pediatr Dermatol"},{"key":"1675_CR22","doi-asserted-by":"publisher","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al (2020) Efficacy https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406","DOI":"10.1001\/jamadermatol.2020.1406"},{"issue":"1","key":"1675_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/bjd\/ljad268","volume":"190","author":"A Igarashi","year":"2023","unstructured":"Igarashi A, Katsunuma T, Matsumura T, Komazaki H, Nemolizumab JPSG (2023) Efficacy and safety of nemolizumab in paediatric patients aged 6\u201312 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. Br J Dermatol 190(1):20\u201328. https:\/\/doi.org\/10.1093\/bjd\/ljad268","journal-title":"Br J Dermatol"},{"issue":"1","key":"1675_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000350486","volume":"162","author":"SR Iyengar","year":"2013","unstructured":"Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT et al (2013) Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 162(1):89\u201393. https:\/\/doi.org\/10.1159\/000350486","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"1675_CR25","doi-asserted-by":"publisher","first-page":"e13642","DOI":"10.1111\/srt.13642","volume":"30","author":"A Jafarzadeh","year":"2024","unstructured":"Jafarzadeh A, Pour Mohammad A, Khosravi M, Amiri S, Rasouli A, Keramati H, Goodarzi A (2024a) A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo. Skin Res Technol. 30(3):e13642. https:\/\/doi.org\/10.1111\/srt.13642","journal-title":"Skin Res Technol."},{"issue":"1","key":"1675_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13287-024-03800-6","volume":"15","author":"A Jafarzadeh","year":"2024","unstructured":"Jafarzadeh A, Pour Mohammad A, Keramati H, Zeinali R, Khosravi M, Goodarzi A (2024b) Regenerative medicine in the treatment of specific dermatologic disorders: a systematic review of randomized controlled clinical trials. Stem Cell Res Ther. 15(1):176. https:\/\/doi.org\/10.1186\/s13287-024-03800-6","journal-title":"Stem Cell Res Ther."},{"key":"1675_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16660","author":"A Jafarzadeh","year":"2024","unstructured":"Jafarzadeh A, Mohammad AP, Goodarzi A (2024c) A systematic review of case series and clinical trials investigating regenerative medicine for the treatment of vitiligo. J Cosmet Dermatol. https:\/\/doi.org\/10.1111\/jocd.16660","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"1675_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","volume":"37","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Chen Y, Yu Q, Shi Y (2023) Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs 37(1):35\u201355. https:\/\/doi.org\/10.1007\/s40259-022-00569-z","journal-title":"BioDrugs"},{"key":"1675_CR75","doi-asserted-by":"crossref","unstructured":"Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K, Liu J, Sasaki T, Chu AD, Teixeira HD, Saeki H (2022) A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): an interim 24-week analysis. JAAD Int 6:27\u201336","DOI":"10.1016\/j.jdin.2021.11.001"},{"issue":"1","key":"1675_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13555-022-00842-7","volume":"13","author":"N Katoh","year":"2023","unstructured":"Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K et al (2023) Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-year interim results from the phase 3 rising up study. Dermatol Ther (Heidelb) 13(1):221\u2013234. https:\/\/doi.org\/10.1007\/s13555-022-00842-7","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1675_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s13555-023-01071-2","volume":"14","author":"N Katoh","year":"2024","unstructured":"Katoh N, Ikeda M, Ohya Y, Murota H, Hu X, Liu J et al (2024) Safety and efficacy of upadacitinib for atopic dermatitis in japan: analysis of the 3-year phase 3 rising up study. Dermatol Ther (Heidelb) 14(1):213\u2013232. https:\/\/doi.org\/10.1007\/s13555-023-01071-2","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"1675_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11882-018-0804-8","volume":"18","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Alexis AF (2018) Biologics and small molecule agents in allergic and immunologic skin diseases. Curr Allergy Asthma Rep. 18(10):55. https:\/\/doi.org\/10.1007\/s11882-018-0804-8","journal-title":"Curr Allergy Asthma Rep."},{"key":"1675_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19063","author":"D Krasowska","year":"2023","unstructured":"Krasowska D, Gambichler T, Cortes C, Horev A, Compagno N, Dahale SS et al (2023) Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: two-year results from a phase III double-blind, randomized controlled trial. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.19063","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1675_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00281-015-0491-7","volume":"37","author":"JB Kuemmerle-Deschner","year":"2015","unstructured":"Kuemmerle-Deschner JB (2015) CAPS\u2013pathogenesis, presentation and treatment of an autoinflammatory disease. Semin Immunopathol 37(4):377\u2013385. https:\/\/doi.org\/10.1007\/s00281-015-0491-7","journal-title":"Semin Immunopathol"},{"issue":"12","key":"1675_CR34","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1136\/ard.2011.152728","volume":"70","author":"JB Kuemmerle-Deschner","year":"2011","unstructured":"Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B et al (2011) Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 70(12):2095\u20132102. https:\/\/doi.org\/10.1136\/ard.2011.152728","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1675_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1684\/ejd.2010.0911","volume":"20","author":"I Landells","year":"2010","unstructured":"Landells I, Paller AS, Pariser D, Kricorian G, Foehl J, Molta C et al (2010) Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis. Eur J Dermatol 20(3):323\u2013328. https:\/\/doi.org\/10.1684\/ejd.2010.0911","journal-title":"Eur J Dermatol"},{"issue":"4","key":"1675_CR36","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","volume":"73","author":"I Landells","year":"2015","unstructured":"Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF et al (2015) Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 73(4):594\u2013603. https:\/\/doi.org\/10.1016\/j.jaad.2015.07.002","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1675_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jaad.2010.02.060","volume":"64","author":"RG Langley","year":"2011","unstructured":"Langley RG, Paller AS, Hebert AA, Creamer K, Weng HH, Jahreis A et al (2011) Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol 64(1):64\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2010.02.060","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1675_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12801","volume":"32","author":"Y Liang","year":"2019","unstructured":"Liang Y, Chen YL, Zhao MT, Wang ZY, Li L, Zhang B, Shen CP, Wang S, Xu ZG, Ma L (2019) Pediatric dermatology-Critical approach to the new treatments. Dermatol Ther 32(4):e12801. https:\/\/doi.org\/10.1111\/dth.12801","journal-title":"Dermatol Ther"},{"issue":"4","key":"1675_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/mco2.181","volume":"3","author":"GH Liu","year":"2022","unstructured":"Liu GH, Chen T, Zhang X, Ma XL, Shi HS (2022) Small molecule inhibitors targeting the cancers. MedComm. 3(4):181. https:\/\/doi.org\/10.1002\/mco2.181","journal-title":"MedComm."},{"issue":"276","key":"1675_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116666","volume":"5","author":"X Luo","year":"2024","unstructured":"Luo X, Ni X, Zhi J, Jiang X, Bai R (2024) Small molecule agents against alopecia: potential targets and related pathways. Eur J Med Chem 5(276):116666. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116666","journal-title":"Eur J Med Chem"},{"issue":"1","key":"1675_CR41","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jaad.2021.08.066","volume":"86","author":"N Magnolo","year":"2022","unstructured":"Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC et al (2022a) A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 86(1):122\u201330. https:\/\/doi.org\/10.1016\/j.jaad.2021.08.066","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"1675_CR42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40272-022-00507-0","volume":"24","author":"N Magnolo","year":"2022","unstructured":"Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC et al (2022b) Efficacy of secukinumab across subgroups and overall safety in pediatric patients with moderate to severe plaque psoriasis: week 52 results from a phase III randomized study. Paediatr Drugs. 24(4):377\u201387. https:\/\/doi.org\/10.1007\/s40272-022-00507-0","journal-title":"Paediatr Drugs."},{"issue":"3","key":"1675_CR43","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4103\/ijmr.IJMR_1471_18","volume":"148","author":"AN Malaviya","year":"2018","unstructured":"Malaviya AN, Mehra NK (2018) A fascinating story of the discovery & development of biologicals for use in clinical medicine. Indian J Med Res 148(3):263\u2013278. https:\/\/doi.org\/10.4103\/ijmr.IJMR_1471_18","journal-title":"Indian J Med Res"},{"issue":"1","key":"1675_CR44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, Ben-Shoshan M et al (2024) Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol 154(1):184\u2013194. https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028","journal-title":"J Allergy Clin Immunol"},{"key":"1675_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-024-01590-0","author":"A Nazerian","year":"2024","unstructured":"Nazerian A, Jafarzadeh A, Salehi S, Ghasemi M, Goodarzi A (2024) Cyclosporin for the treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): a systematic review of observational studies and clinical trials focusing on single therapy, combination therapy, and comparative assessments. Inflammopharmacology. https:\/\/doi.org\/10.1007\/s10787-024-01590-0","journal-title":"Inflammopharmacology"},{"issue":"4","key":"1675_CR46","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.aller.2020.03.011","volume":"48","author":"M Ocak","year":"2020","unstructured":"Ocak M, Soyer O, Buyuktiryaki B, Sekerel BE, Sahiner UM (2020) Omalizumab treatment in adolescents with chronic spontaneous urticaria: efficacy and safety. Allergol Immunopathol (Madr) 48(4):368\u2013373. https:\/\/doi.org\/10.1016\/j.aller.2020.03.011","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"3","key":"1675_CR47","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/nejmoa066886","volume":"358","author":"AS Paller","year":"2008","unstructured":"Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 358(3):241\u2013251. https:\/\/doi.org\/10.1056\/nejmoa066886","journal-title":"N Engl J Med"},{"issue":"2","key":"1675_CR48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","volume":"74","author":"AS Paller","year":"2016","unstructured":"Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J et al (2016) Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 74(2):280\u20137 e1-3. https:\/\/doi.org\/10.1016\/j.jaad.2015.09.056","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"1675_CR49","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Thaci D, Wollenberg A, Cork MJ, Arkwright PD et al (2020a) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 83(5):1282\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"1675_CR50","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjd.19147","volume":"183","author":"AS Paller","year":"2020","unstructured":"Paller AS, Seyger MMB, Alejandro Magarinos G, Bagel J, Pinter A, Cather J et al (2020b) Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 183(2):231\u201341. https:\/\/doi.org\/10.1111\/bjd.19147","journal-title":"Br J Dermatol."},{"issue":"2","key":"1675_CR51","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jaad.2019.08.019","volume":"82","author":"AS Paller","year":"2020","unstructured":"Paller AS, Hong Y, Becker EM, de Lucas R, Paris M, Zhang W et al (2020c) Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. J Am Acad Dermatol. 82(2):389\u201397. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.019","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"1675_CR52","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jdv.16928","volume":"35","author":"AS Paller","year":"2021","unstructured":"Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP et al (2021) A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol 35(2):464\u2013475. https:\/\/doi.org\/10.1111\/jdv.16928","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10356","key":"1675_CR53","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/s0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD et al (2022a) Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 400(10356):908\u201319. https:\/\/doi.org\/10.1016\/s0140-6736(22)01539-2","journal-title":"Lancet."},{"issue":"5","key":"1675_CR54","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamadermatol.2022.0655","volume":"158","author":"AS Paller","year":"2022","unstructured":"Paller AS, Seyger MMB, Magarinos GA, Pinter A, Cather JC, Rodriguez-Capriles C et al (2022b) Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. 158(5):533\u201341. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0655","journal-title":"JAMA Dermatol."},{"issue":"7","key":"1675_CR55","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s13555-023-00942-y","volume":"13","author":"AS Paller","year":"2023","unstructured":"Paller AS, Flohr C, Eichenfield LF, Irvine AD, Weisman J, Soung J et al (2023) Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-week, open-label, phase 3 study. Dermatol Ther (Heidelb) 13(7):1517\u20131534. https:\/\/doi.org\/10.1007\/s13555-023-00942-y","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1675_CR56","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s12325-023-02753-1","volume":"41","author":"AS Paller","year":"2024","unstructured":"Paller AS, Pinter A, Wine Lee L, Aschoff R, Zdybski J, Schnopp C et al (2024a) Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 months to 5 years with severe atopic dermatitis. Adv Ther. 41(3):1046\u201361. https:\/\/doi.org\/10.1007\/s12325-023-02753-1","journal-title":"Adv Ther."},{"issue":"4","key":"1675_CR57","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40257-024-00859-y","volume":"25","author":"AS Paller","year":"2024","unstructured":"Paller AS, Siegfried EC, Simpson EL, Cork MJ, Sidbury R, Chen IH et al (2024b) Dupilumab safety and efficacy up to 1 year in children aged 6 months to 5 years with atopic dermatitis: results from a phase 3 open-label extension study. Am J Clin Dermatol. 25(4):655\u201368. https:\/\/doi.org\/10.1007\/s40257-024-00859-y","journal-title":"Am J Clin Dermatol."},{"issue":"10089","key":"1675_CR58","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/s0140-6736(17)31189-3","volume":"390","author":"K Papp","year":"2017","unstructured":"Papp K, Thaci D, Marcoux D, Weibel L, Philipp S, Ghislain PD et al (2017) Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet 390(10089):40\u201349. https:\/\/doi.org\/10.1016\/s0140-6736(17)31189-3","journal-title":"Lancet"},{"issue":"1","key":"1675_CR59","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2174\/0929867323666151117121706","volume":"23","author":"P Portincasa","year":"2016","unstructured":"Portincasa P (2016) Colchicine, biologic agents and more for the treatment of familial mediterranean fever. The old, the new, and the rare. Curr Med Chem. 23(1):60\u201386. https:\/\/doi.org\/10.2174\/0929867323666151117121706","journal-title":"Curr Med Chem."},{"issue":"10290","key":"1675_CR60","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/s0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K et al (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397(10290):2169\u20132181. https:\/\/doi.org\/10.1016\/s0140-6736(21)00589-4","journal-title":"Lancet"},{"issue":"3","key":"1675_CR61","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s13555-021-00678-7","volume":"12","author":"R Sidbury","year":"2022","unstructured":"Sidbury R, Alpizar S, Laquer V, Dhawan S, Abramovits W, Loprete L et al (2022) Pharmacokinetics, safety, efficacy, and biomarker profiles during nemolizumab treatment of atopic dermatitis in adolescents. Dermatol Ther (Heidelb) 12(3):631\u2013642. https:\/\/doi.org\/10.1007\/s13555-021-00678-7","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1675_CR62","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jaad.2009.10.046","volume":"63","author":"EC Siegfried","year":"2010","unstructured":"Siegfried EC, Eichenfield LF, Paller AS, Pariser D, Creamer K, Kricorian G (2010) Intermittent etanercept therapy in pediatric patients with psoriasis. J Am Acad Dermatol 63(5):769\u2013774. https:\/\/doi.org\/10.1016\/j.jaad.2009.10.046","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1675_CR63","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP et al (2020) Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 156(8):863\u2013873. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406","journal-title":"JAMA Dermatol."},{"issue":"10246","key":"1675_CR64","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S et al (2020a) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 396(10246):255\u2013266. https:\/\/doi.org\/10.1016\/s0140-6736(20)30732-7","journal-title":"Lancet."},{"issue":"1","key":"1675_CR65","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ et al (2020b) Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 156(1):44\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336","journal-title":"JAMA Dermatol."},{"issue":"6","key":"1675_CR66","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jaad.2023.12.066","volume":"90","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Worm M, Honari G, Masuda K, Sygula E et al (2024) Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 90(6):1190\u20131199. https:\/\/doi.org\/10.1016\/j.jaad.2023.12.066","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1675_CR67","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.15665","volume":"177","author":"CH Smith","year":"2017","unstructured":"Smith CH, Jabbar-Lopez ZK, Yiu ZZ et al (2017) British association of dermatologists guidelines for biologic therapy for psoriasis. Br J Dermatol 177(3):628\u2013636. https:\/\/doi.org\/10.1111\/bjd.15665","journal-title":"Br J Dermatol"},{"issue":"11","key":"1675_CR68","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3389\/fimmu.2020.00865","volume":"3","author":"A Soriano","year":"2020","unstructured":"Soriano A, Soriano M, Espinosa G, Manna R, Emmi G, Cantarini L et al (2020) Current therapeutic options for the main monogenic autoinflammatory diseases and PFAPA syndrome: evidence-based approach and proposal of a practical guide. Front Immunol 3(11):865. https:\/\/doi.org\/10.3389\/fimmu.2020.00865","journal-title":"Front Immunol"},{"issue":"7","key":"1675_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13982","volume":"34","author":"P Staubach","year":"2023","unstructured":"Staubach P, Alvaro-Lozano M, Sekerel BE, Maurer M, Ben-Shoshan M, Porter M et al (2023) Ligelizumab in adolescents with chronic spontaneous urticaria: results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. Pediatr Allergy Immunol 34(7):e13982. https:\/\/doi.org\/10.1111\/pai.13982","journal-title":"Pediatr Allergy Immunol"},{"issue":"6","key":"1675_CR70","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/bjd.18029","volume":"181","author":"D Thaci","year":"2019","unstructured":"Thaci D, Papp K, Marcoux D, Weibel L, Pinter A, Ghislain PD et al (2019) Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol 181(6):1177\u20131189. https:\/\/doi.org\/10.1111\/bjd.18029","journal-title":"Br J Dermatol"},{"issue":"1","key":"1675_CR71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"A Torrelo","year":"2023","unstructured":"Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, Prakash A et al (2023) Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol 189(1):23\u201332. https:\/\/doi.org\/10.1093\/bjd\/ljad096","journal-title":"Br J Dermatol"},{"issue":"8","key":"1675_CR72","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3390\/children11080892","volume":"11","author":"RC Yi","year":"2024","unstructured":"Yi RC, Moran SK, Gantz HY, Strowd LC, Feldman SR (2024) Biologics and small molecule targeted therapies for pediatric alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa in the US: a narrative review. Children 11(8):892. https:\/\/doi.org\/10.3390\/children11080892","journal-title":"Children"},{"issue":"3","key":"1675_CR73","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ped4.12400","volume":"7","author":"A Zhao","year":"2023","unstructured":"Zhao A, Pan C, Li M (2023) Biologics and oral small-molecule inhibitors for treatment of pediatric atopic dermatitis: opportunities and challenges. Pediatr Investig 7(3):177\u2013190. https:\/\/doi.org\/10.1002\/ped4.12400","journal-title":"Pediatr Investig"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01675-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01675-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01675-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:16:30Z","timestamp":1744492590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01675-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1675"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01675-4","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that there is no conflict of interest for this project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All collected data were kept confidential and analysed without specific names attached. The study adhered to Helsinki ethical principles. The project was registered at Iran University of Medical Sciences with registration No. IR.IUMS.SD5338632476231Z1, bearing the scientific title \u201cEmerging Treatments for Dermatologic Diseases in Infants, Children, and Adolescents: A Systematic Review of Clinical Trials on Biologics and Small Molecule Inhibitors\u201d It was approved by the Research Council under the ethics code number IR.IUMS.FMD.REC.1403.532.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors obtained consent to publish. The current manuscript contains no individual person\u2019s data. Therefore, consent to publish is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}